An unexplored but promising therapy is the clinical use of prolactin since administration with prolactin or prolactin-releasing peptide evidently improves steatosis in mice obesity models (137), and ablation of prolactin receptor increases hepatic triglyceride accumulation (193). Here, PRL is linked to obesity disorder.